SHERIDAN, WYOMING – May 9, 2025 – Galderma Group AG, a global leader in dermatology, has announced a stellar first quarter of 2025, reporting a net sales total of 1.129 billion USD, reflecting an 8.3% year-on-year growth. This performance highlights the continued success of the company’s broad portfolio and strategic execution, setting a promising tone for the rest of the year.
Strong Start to 2025
Galderma’s impressive Q1 results were driven by robust performance across its diverse product categories. The company’s broad-based growth across geographies, combined with favorable market dynamics, fueled significant sales momentum. This includes a standout performance from its injectable aesthetics and dermatological skincare segments, marking the launch of two products—Nemluvio and Relfydess—both with blockbuster potential.
CEO Flemming Ørnskov expressed his confidence, stating, “Galderma is off to an outstanding start in 2025. Our broad-based performance across all product categories and geographies perfectly illustrates the power of our unique Integrated Dermatology Strategy.”
Market-Wide Growth Across All Categories
Galderma’s first-quarter results demonstrate impressive performance across three key categories: Injectable Aesthetics, Dermatological Skincare, and Therapeutic Dermatology.
- Injectable Aesthetics saw a remarkable 9.9% growth in net sales, reaching 547 million USD. The company reported a 21.4% increase in sales of neuromodulators, a critical subcategory of injectable aesthetics, which contributed significantly to this growth.
- Dermatological Skincare, with flagship brands like Cetaphil and Alastin, posted strong performance, particularly in international markets. The introduction of new products, such as Cetaphil’s Acne Fast Rescue Pimple Patches and Alastin’s Restorative Skin Complex, helped drive consumer engagement.
- Therapeutic Dermatology also saw positive results, with the successful launch of Nemluvio, which generated 39 million USD in sales. Nemluvio, targeting conditions like atopic dermatitis and prurigo nodularis, showed strong uptake across the U.S. and international markets, contributing to overall growth in the category.
Innovation and Expansion Drive Future Growth
Looking ahead, Galderma is optimistic about the continued success of its product portfolio and upcoming launches. The company is positioning itself for long-term growth, with plans to expand into new markets and deepen its consumer reach. The launch of products like Relfydess and Sculptra in China, along with Restylane SHAYPE™ in Brazil, presents significant opportunities for market share capture in underpenetrated regions.
Additionally, the company’s efforts to innovate within the skincare space continue with the expansion of Cetaphil and Alastin products, which are being targeted at Gen Z consumers through strategic rebranding campaigns. These innovations are expected to bolster the company’s market presence and support sustained growth.
Full-Year Outlook and Continued Focus on Execution
With a strong Q1 performance, Galderma is maintaining its full-year guidance for 2025. The company anticipates net sales growth of 10-12% at constant currency and a Core EBITDA margin of approximately 23%. While the ongoing economic and geopolitical challenges may present some headwinds, Galderma’s broad portfolio and international exposure position it well for continued success.
Ørnskov concluded, “With these achievements and despite the ongoing economic and geopolitical volatility, we are confident that we are firmly on track to meet our 2025 outlook.”
Galderma’s record-setting quarter and strong outlook highlight the company’s ability to innovate and deliver value to consumers and healthcare professionals alike.
Learn more about Galderma's latest innovations and product launches at www.galderma.com.